



Vaccines and Global Health: The Week in Review
07 September 2024 :: Issue 765
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

Milestones, Perspectives

.....
.....

Gaza – Polio vaccination

First phase of polio campaign concludes successfully in Gaza

4 September 2024 WHO News release

Over 187 000 children under ten years of age were vaccinated with novel oral polio vaccine type 2 (nOPV2) in central Gaza during the first phase of a two-round polio vaccination campaign, conducted between 1–3 September 2024. Vaccination **coverage in this phase exceeded the initial estimated target of 157 000 children due to population movement towards central Gaza, and expanded coverage in areas outside the humanitarian pause zone.**

To ensure no child is missed in this area, **polio vaccination will continue at four large health facilities in central Gaza over the next few days.** Vaccine doses have been supplied to these sites to meet any additional needs...

Notes to editors

- The campaign is part of an urgent response to prevent the spread of polio after circulating variant poliovirus type 2 (cVDPV2) was detected in Gaza, after 25 years of being polio-free. cVDPV2 has been detected in six environmental samples – or wastewater – collected from central Gaza in June 2024. Gaza has reported four cases of children with acute flaccid paralysis (AFP), including one case of confirmed polio in a child who tested positive for circulating variant poliovirus type 2 (cVDPV2). Two of the reported cases tested negative for poliovirus. Laboratory results are pending on samples from the fourth AFP case.
- Novel oral polio vaccine (nOPV2) is a polio vaccine being used to stop transmission of variant poliovirus type 2 (cVDPV2), currently the most prevalent form of the variant poliovirus.
- nOPV2 is safe and effective and offers protection against paralysis and community transmission. It is the vaccine globally recommended for variant type 2 poliovirus outbreaks – the type that has been found in the recent samples from Gaza.

.....

Statement by UNICEF Regional Director for the Middle East and North Africa, Adele Khodr, on the completion of the first phase of the polio vaccination campaign in the Gaza Strip

AMMAN, 4 SEPTEMBER 2024 – “The past three days have brought a rare bright spot amid the disastrous conflict in the Gaza Strip...

“For at least a quarter of a century, there were no cases of polio in the Gaza Strip. Now from the depths of untreated sewage and rubble, the invisible menace is back. So far, one case of polio has been confirmed in an 11-month-old baby – a child whose short life has already been punctuated by the most challenging circumstances and who will now suffer irreparable physical harm.

“The risk of polio spreading within Gaza and even beyond, especially to neighbouring countries, remains high. This week, we began to address it. UNICEF, UNRWA and WHO are working tirelessly to roll out a campaign in Gaza to vaccinate 640,000 children under 10 years of age.

“The first phase of the campaign, which ran from 1-3 September, reached more than 189,000 children

under 10 years old in the central area of the Gaza Strip, surpassing its initial target. **Approximately 513 teams were deployed across the area...**

"However, none of this can be achieved without the area-specific humanitarian pauses to ensure healthcare workers and children can engage in the campaign without risking their lives. The agreed pauses were respected in this first phase, giving families and health workers the confidence to get the job done.

"This must continue. **Without a polio pause to implement the remaining two phases of the campaign, we will fail to protect the children of Gaza and place other children in the region at risk. We must reach at least 90 per cent vaccination coverage to stop the virus from spreading...**

"This is among the most dangerous and difficult vaccination campaigns on the planet. The Gaza Strip is already the most dangerous place in the world to be a child, and even with a polio pause, the vaccination campaign faces grave danger and immeasurable obstacles, including damaged roads and health infrastructure, displaced populations, looting and disrupted supply routes.

"Children have suffered enough. And now the stakes have risen to threatening other children in the region. We cannot fail."

.....
.....

Mpox - PHEIC

[WHO delivers 14 tons of emergency supplies for mpox response in the Democratic Republic of the Congo](#)

07 September 2024

Nairobi/Kinshasa – World Health Organization (WHO) today delivered 14 metric tons of medical supplies and equipment to the Democratic Republic of the Congo to support infection prevention and control and case management for the ongoing response to halt the mpox outbreak.

The supplies consist of personal protective equipment, tents, treatments and other medical supplies, sufficient to support clinical care for 16 800 people for three months. The consignment was shipped from WHO Emergency Preparedness Hub in Nairobi, Kenya. This is the **first of several deliveries to the Democratic Republic of Congo in the coming weeks, the total value of which amounts to US\$ 1 million.**

"These supplies will ensure health facilities have the critical items needed to provide safe and optimal care to patients, contributing to the ongoing emergency response by the health authorities, with support from WHO and other partners," said Dr Matshidiso Moeti, WHO Regional Director for Africa...

.....

[African CDC and WHO Launch Joint Continental Plan to Scale Up Mpox Outbreak Response](#)

KINSHASA, 6 September 2024 – In a significant step to strengthen and accelerate the response to the ongoing the mpox outbreak, the Africa Centres for Disease Control and Prevention (Africa CDC) and World Health Organization (WHO) today launched a joint continental response plan for Africa to support countries' efforts to curb the spread of the virus, save and protect lives.

The launch of the **Mpox Strategic Preparedness and Response Plan** follows the declarations of a public health emergency of continental security (PHECS) on 13 August 2024 by Africa CDC, and a public health emergency of international concern (PHEIC) on 14 August 2024 by WHO.

"We are proud to jointly launch this plan which unites all stakeholders in a coordinated approach to tackling the mpox outbreaks across Africa," said Dr Jean Kaseya, Africa CDC Director General. "This unified strategy ensures that all partners are aligned on common objectives, eliminating duplication and maximizing impact."

The overall estimated budget for the six-month plan, running from September 2024 to February 2025, is close to US\$ 600 million with 55% allocated to mpox response in 14 affected Member States and readiness in 15 other Member States, while 45% is directed towards operational and technical support through partners.

...The Mpox Strategic Preparedness and Response Plan emphasizes a **community-centred, multisectoral approach tailored to the unique epidemiology and risk profiles of each Member state**. The plan bolsters surveillance, laboratory testing, community engagement, and ensures the availability of critical countermeasures, while building resilient and equitable health systems.

Under the plan, Member States are classified into four categories based on their mpox status and risk level:

1. Countries with sustained human-to-human transmission;
2. Countries with sporadic human cases since January 2022 or endemic zoonotic reservoirs;
3. Countries needing enhanced readiness due to proximity to countries with ongoing transmission;
4. All other countries not part of the three categories.

Priority actions are outlined for each category to guide national strategies in responding to the mpox epidemic. The plan includes measures to strengthen surveillance, laboratory detection, case management, infection prevention and control (IPC), vaccination, risk communication and community engagement (RCCE) and research and innovation.

This continental response, co-coordinated by Africa CDC and WHO, is supported by workstreams led by key partners, leveraging their comparative advantages. WHO and Africa CDC will collaborate with stakeholders, including UN agencies, non-governmental organizations, and civil society, which will participate in relevant pillars of the response. **In line with the Lusaka Agenda, the mpox response will follow the "one team, one plan, one budget, one M&E" approach. To that end, a continental Incident Management Team has been established, comprising members from key partners.**

.....

Press Releases

[Joint Press Release: The Democratic Republic of Congo receives first Mpox vaccines](#)

Kinshasa, 5 September 2024 – The Africa Centres for Disease Control and Prevention (Africa CDC) and United Nations Children's Fund (UNICEF) are pleased to announce the arrival of the first shipment of 99,100 doses of JYNNEOS mpox vaccine. This shipment is expected to launch a critical vaccination campaign aimed at curbing the rising epidemic in the Democratic Republic of Congo (DRC)...

Press Releases

[La RDC réceptionne les premiers vaccins contre la Mpox](#)

Kinshasa, 5 septembre 2024 – Les Centres africains de contrôle et de prévention des maladies (Africa CDC) et le Fonds des Nations Unies pour l'Enfance (UNICEF) ont le plaisir d'annoncer l'arrivée de la première livraison de 99 100 doses de vaccin contre la mpox JYNNEOS. Cet envoi devrait permettre de lancer une campagne de vaccination cruciale visant à contrôler l'épidémie de mpox en République démocratique du Congo (RDC)...

.....
.....

Immunization – DPRK

Nearly one million children and pregnant women in the Democratic People's Republic of Korea to receive life-saving routine vaccines

Government launches largest catch-up vaccination campaign following the COVID-19 pandemic

BANGKOK, 3 September 2024 – More than 800,000 children and 120,000 pregnant women will be vaccinated in a nationwide campaign launched on Monday by the Government of the Democratic People's Republic of Korea (DPRK) with UNICEF support.

The vaccination campaign will reach children and pregnant women in all 210 counties who have missed out on life-saving vaccines since the COVID-19 pandemic began in 2020.

"This campaign is a major milestone in our drive to vaccinate every child in the DPRK and protect them from common childhood diseases," said UNICEF DPRK Acting Representative Roland Kupka. "This is the first step in restoring routine immunization and closing the gap that has left children vulnerable to preventable diseases."

With support from Gavi, the Vaccine Alliance, UNICEF assisted the Ministry of Public Health with the delivery of over four million doses of essential vaccines — including Pentavalent, Measles-Rubella (MR), Tetanus-Diphtheria, BCG, Hepatitis B, and Inactivated Poliovirus Vaccine (IPV) — to the DPRK in July to kickstart this comprehensive catch-up effort. Of these, two million doses will be used in the current catch-up vaccination campaign, while the rest will be sent to health centers nationwide to boost routine immunization programs.

National immunization rates in the DPRK exceeded 96 per cent before the COVID-19 pandemic but had dropped to below 42 per cent by mid-2021, leaving countless children at risk of deadly diseases such as polio, diphtheria, measles, rubella, and hepatitis.

UNICEF has supported three previous catch-up vaccination campaigns in the DPRK between 2021 and 2023, reaching a combined total of nearly 1.3 million children who missed essential vaccinations during the pandemic's peak. Additional shipments are expected to reach the DPRK by the end of this year.

UNICEF also supplied new freezers, fridges, cold boxes, and temperature taggers to keep vaccines effective in even the most remote areas. Additionally, **over 7,200 health workers were trained** to manage vaccination campaigns and handle any potential vaccine reactions. UNICEF is also supporting the campaign by overseeing vaccine delivery and administration, and tracking coverage to ensure its success.

"To sustain progress in restoring pre-pandemic vaccination levels and ensuring every child receives essential, life-saving vaccines, we urge the DPRK government to swiftly allow the return of UNICEF and UN international staff in the country," said Kupka.



Cholera

Data show marked increase in annual cholera deaths

4 September 2024 WHO News release

The World Health Organization (WHO) has published [global cholera statistics for 2023](#), showing an increase in cases and deaths.

The number of reported cholera cases increased by 13% and deaths by 71% in 2023 compared to 2022. **Over 4000 people died** last year from a disease that is preventable and easily treatable.

Forty-five countries reported cases, an increase from 44 the previous year and 35 in 2021.

Thirty-eight per cent of the reported cases were among children under five years of age...Conflict, climate change, inadequate safe water and sanitation, poverty, underdevelopment, and population displacement due to emerging and re-emerging conflicts and disasters from natural hazards all contributed to the rise in cholera outbreaks last year.

The geographical distribution of cholera changed significantly from 2022 to 2023, with a 32% decrease in cases reported from the Middle East and Asia, and a 125% increase in Africa. Many countries in Africa reported a high proportion of community deaths, indicating gaps in access to treatment.

This is the first year that multiple countries have reported deaths from cholera which occurred outside of health facilities, known as 'community deaths'. In five out of 13 reporting countries, over a third of cholera deaths occurred in the community, highlighting serious gaps in access to treatment and the need to strengthen this area of response.

Afghanistan, the Democratic Republic of the Congo, Malawi and Somalia continued to report large outbreaks of over 10 000 suspected or confirmed cases, with Ethiopia, Haiti, Mozambique and Zimbabwe adding to the tally in 2023...

The increased demand for cholera materials such as oral cholera vaccines (OCV), diagnostic tests and essential medications like oral rehydration salts and intravenous fluids for rehydration persists into 2023, posing a challenge for disease control efforts globally.

Since October 2022, the International Coordinating Group (ICG), which manages emergency vaccine supplies, has **suspended the standard two-dose vaccination regimen in cholera outbreak response** campaigns, adopting a single-dose approach instead in order to reach and protect more people given limited supplies.

Despite the low stockpile of OCV, a record 35 million doses were shipped last year, with the one-dose strategy in effect. While vaccination is an important tool, safe drinking water, sanitation and hygiene remain the only long-term and sustainable solutions to ending cholera outbreaks and preventing future ones.

WHO considers the current global risk from cholera as very high and is responding with urgency to reduce deaths and contain outbreaks in countries around the world. WHO continues to support countries through strengthened public health surveillance, case management, and prevention

measures; provision of essential medical supplies; coordination of field deployments with partners; and support for risk communication and community engagement.

US\$ 18 million has been released from the WHO Contingency Fund for Emergencies for cholera response since 2022. WHO has appealed for US\$ 50 million to respond to cholera outbreaks in 2024, but this need remains unmet.

.....

Cholera, 2023

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 99, No. 36, pp. 457–496 6 September 2024

PDF: <https://iris.who.int/bitstream/handle/10665/378642/WER9935-eng-fre.pdf>

[Excerpt]

...Editorial note

WHO and partners support cholera-affected countries in implementing immediate and long-term control measures, including surveillance, outbreak response, WASH and preventive measures such as OCV and risk communication and community engagement (RCCE).

WHO continues to host the secretariat of the GTFCC, a partnership to coordinate global cholera-related activities and support countries. The GTFCC advocates for long-term cholera control based on multi-sectoral national cholera plans (NCPs).

Since the 2017 launch of the *Ending Cholera: A Global Roadmap to 2030* strategy, GTFCC partners have collaborated to establish **a support system for cholera-affected countries, including the country support platform hosted by the International Federation of Red Cross and Red Crescent Societies**, which provides multisectoral operational and technical support and guidance on advocacy, coordination and policy to develop, fund, implement and monitor NCPs.

Several GTFCC technical working groups, each with a designated WHO focal point, provide specific guidance. Links to new GTFCC documents and up-to-date guidelines and reports are provided throughout this report. The GTFCC app remains a valuable tool for national cholera control [<https://www.gtfcc.org/cholera-app/>].

Under-reporting or no reporting of cholera cases and deaths remains too frequent, posing significant challenges to early detection and response. This issue also hinders accurate assessment of the true cholera burden and undermines advocacy for greater investment in sustainable cholera control.

Identification of priority areas for multisectoral intervention (PAMIs, formerly referred to as “hotspots”) is one of the first steps in developing or revising NCPs. In 2023, 2 new methods for identifying PAMIs for NCPs were published, 1 for countries targeting cholera control and the other for countries targeting cholera elimination.¹⁰ In early 2024, updated guidance for cholera surveillance¹¹ and a method to assess its effectiveness¹² were released to support timely, targeted interventions. Notably, the guidance recommends increased use of RDTs for early outbreak detection, incidence monitoring and laboratory confirmation using culture methods or PCR. To facilitate enhanced use of RDTs, a global cholera RDT procurement programme funded by GAVI, the Vaccine Alliance, in partnership with WHO, UNICEF and Find has approved and is deploying 1.4 million RDTs to 16 countries.

Thirteen countries reported data on facility and community deaths, 4 indicating that >40% of deaths occurred in the community. This highlights the importance of better access to treatment during

outbreaks. To address this, the case management working group published recommendations to guide rapid establishment and management of ORPs.¹³

Effective cholera control requires community involvement in responses. In 2024, the GTFCC published guidance on integrating RCCE into NCPs.¹⁴

In 2023, 28 requests for 72 million doses of OCV were made, and 36.6 million doses (all the available doses) were approved for emergency response and shipped to 12 countries (Cameroon, Dominican Republic, DRC, Ethiopia, Haiti, Kenya, Malawi, Mozambique, Somalia, Sudan, Syrian Arab Republic and Zambia). **GAVI approved 2 requests for OCV for preventive campaign from Bangladesh and DRC.**

A record 35 million OCV doses were shipped, with the 1-dose strategy still in effect. Multinational workshops were held to enhance country capacity in OCV use, including analysis and practical tools for supporting OCV requests

.....
.....

Pathogens

[WHO launches global framework for understanding the origins of new or re-emerging pathogens](#)

4 September 2024 WHO News release

With the support of the Scientific Advisory Group for the Origins of Novel Pathogens (SAGO), the World Health Organization (WHO) has published a [global framework](#) to help Member States comprehensively investigate the origins of new and re-emerging pathogens. While there are a number of tools available for investigating infectious disease outbreaks, this is the **first unified, structured approach to investigating the origins of a novel pathogen**. This framework aims to fill that gap by providing a comprehensive set of scientific investigations and studies. It is the first version of a “how-to” guide that will be updated as and when needed, based on feedback from users.

As each outbreak and pandemic demonstrates, human and animal health is threatened by the increasing risk of the emergence of known (such as Ebola, Nipah, avian influenza, Lassa and Monkeypox viruses) and novel pathogens with epidemic and pandemic potential (novel influenza, MERS-CoV, SARS-CoV-1, SARS-CoV-2), the ability to prevent, and when we cannot prevent, to swiftly contain outbreaks and identify their origins is scientifically, morally, and financially more critical than ever.

The WHO global framework outlines scientific investigations and studies for six technical elements:

- *Early investigations* of the first identified cases/ clusters / outbreaks to identify potential sources of exposure, collection of samples at the source, define the characteristics of the novel pathogen involved for establishment of diagnostic assays.
- *Human studies*: to understand the epidemiology including clinical presentation, modes of transmission, pathology and earliest presence in syndromic surveillance samples.
- *Human/Animal interface studies* to identify potential animal reservoirs, intermediate hosts and reverse zoonoses.
- *Studies to identify insect vectors* or other sources of infection as well as earliest presence in the environment. ...
- *Genomics and Phylogenetics studies* to identify precursor strains, genomic characteristics, evolution in intermediate hosts and humans and spatial distribution over time.

- *Biosafety/Biosecurity studies* to determine if a breach in laboratory or research activities may have been associated with the first cases...

.....
.....

COVID Vaccines Procurement – Transparency

European Union: General Court Rules European Commission Must Grant Wider Access to COVID-19 Vaccine Purchase Agreements

Global Legal Monitor & Legal Reports – Library of Congress/USA

Article

On July 17, 2024, the General Court of the European Union (EU) held that under an EU freedom of information law, the European Commission (Commission) failed to give sufficient public access to COVID-19 vaccine purchase agreements. Six members of the European Parliament (MEPs) had brought an action for annulment before the court and requested access to the documents.

Background

...In April 2020, the EU decided to jointly procure COVID-19 vaccines for the member states through the Commission by concluding advance purchase agreements with vaccine producers. (COM (2020) 245 final, at 2.) **In 2021, six MEPs requested access to existing and future contracts between the Commission and pharmaceutical companies regarding these procurements. They based their request on the right of access to documents of the institutions accorded to any EU citizen** by article 2, paragraph 1 of Regulation (EC) No. 1049/2001. The Commission's Directorate-General for Health and Food Safety granted access to redacted versions of nine documents and invoked exceptions to the right of access, arguing their disclosure would undermine the protection of privacy and the integrity of the individual or commercial interests of those concerned. (Regulation (EC) No. 1049/2001, art. 4, para.1(b), para. 2, indent 1.)

The MEPs requested wider access to the documents insofar as the redactions were based on the protection of commercial interests, arguing in particular that certain redacted information had already been leaked in the media. They specifically requested access to the redacted definitions of the expressions "wilful misconduct" and "best reasonable efforts" in agreements with vaccine producers AstraZeneca and Pfizer-BioNTech. The Commission reexamined the initial response and granted wider partial access to eight of the documents and partial access to four additional documents. It did not grant access to the definitions requested in the MEPs' application and did not indicate why these definitions were redacted while others were not. (Decision, para. 42.)

The court annulled the Commission's decision to refuse access to definitions of "wilful misconduct" and "best reasonable efforts" in agreements with AstraZeneca and Pfizer-BioNTech, and to provisions on donations and resales of vaccines and indemnifications in purchase agreements. (Holding.) Regarding the redacted definitions, the court held that the Commission failed to sufficiently explain how access could undermine the commercial interests of the companies...

Similarly, **the court found the Commission did not sufficiently explain why the contract provisions on donations and resales were redacted, especially by failing to specify how disclosure could damage the companies' competitive positions.** (Para. 185.)...

Prepared by Lena Bleckmann, Law Library Intern, under the supervision of Jenny Gesley, Foreign Law Specialist

.....
.....

Regulatory Tools

[Harnessing AI in medicines regulation: use of large language models \(LLMs\)](#)

Guiding principles set out how EU medicine regulators can use LLMs in a safe, responsible and effective manner

5 September 2024

[Guiding principles on the use of large language models in regulatory science and for medicines regulatory activities](#)

English (EN) (198.5 KB - PDF)

...LLMs also present challenges, e.g. variability in results, returning of irrelevant or inaccurate responses (so-called hallucinations), and potential data security risks. The purpose of the guiding principles is to build understanding of the capabilities and limitations of these applications among staff at regulatory agencies across the EU so that they can harness the potential of LLMs effectively and avoid pitfalls and risks.

The guiding principles cover various aspects of using LLMs, from ensuring safe input of data, to applying critical thinking and cross-checking outputs, to knowing whom to consult when concerns arise. Responsible use of LLMs requires familiarity with the tools. The importance of continuous learning is emphasised to keep pace with the fast-changing field.

Additionally, the principles encourage regulatory agencies to make efforts to support their staff in using LLMs. This includes defining governance on the use of LLMs, specifying permitted use cases, providing training and monitoring risks.

The guiding principles are one of the deliverables of the multiannual AI workplan to 2028 by EMA and the Heads of Medicines Agencies (HMA). This workplan guides EMA and the EMRN in their use of AI, maximising the benefits while managing the risks, and facilitating information sharing.

The guiding principles are a living document that will be regularly updated, and EMA will introduce it to the network in a webinar on 13 September 2024...

.....
.....

Polio – PHEIC

[Polio this week as of 04 September 2024 - GPEI](#)

:: Gaza response to detected variant poliovirus type 2 (cVDPV2) continues: A two-round polio vaccination campaign kicked off on 1 September 2024 in Gaza, in the occupied Palestinian territory (oPt). During each round of the campaign, the Palestinian Ministry of Health (MOH), in collaboration with the World Health Organization (WHO), the United Nations Children's Fund (UNICEF), the United Nations Relief and Works Agency for Palestine Refugees (UNRWA) and partners, will provide two drops of novel oral polio vaccine type 2 (nOPV2) to more than 640,000 children under ten years of age. The campaign began successfully with all showing strong commitment. [More](#).

Summary of new polioviruses this week, cases and positive environmental isolates:

- Afghanistan: 1 WPV1 case
- Pakistan: 8 WPV1-positive environmental samples
- Côte d'Ivoire: 1 cVDPV2-positive environmental sample
- DR Congo: two cVDPV2 cases
- Egypt: 1 cVDPV2-positive environmental sample
- Indonesia: 3 cVDPV2 cases

- Niger: 2 cVDPV2 cases and 3 cVDPV2-positive environmental samples
- Nigeria: 7 cVDPV2 cases and 1 cVDPV2-positive environmental sample
- South Sudan: 2 cVDPV2-positive environmental samples
- Sudan: 1 cVDPV2-positive environmental sample

.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)
 :: [*WHO*](#)
 :: [*Organization Announcements*](#)
 :: [*Journal Watch*](#)
 :: [*Pre-Print Servers*](#)

.....

WHO & Regional Offices [to 07 Sep 2024]

<https://www.who.int/news>

Selected News/Announcements/Statements

4 September 2024 *News release*

[**First phase of polio campaign concludes successfully in Gaza**](#)

4 September 2024 *News release*

[**WHO launches global framework for understanding the origins of new or re-emerging pathogens**](#)

4 September 2024 *News release*

[**Data show marked increase in annual cholera deaths**](#)

3 September 2024 *News release*

[**New global guidance aims to curb antibiotic pollution from manufacturing**](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

:: 07 September 2024

[**WHO delivers 14 tons of emergency supplies for mpox response in the Democratic Republic of the Congo**](#)

WHO Region of the Americas PAHO

:: 4 Sep 2024

[**Antimicrobial resistance, One Health, and climate change top of the agenda at G20 event in Brazil**](#)

Natal, 4 September 2024 (PAHO/WHO) – The Pan American Health Organization (PAHO) recently led a series of discussions on crucial health issues during a G20 health working group meeting from 1-3 September in Natal, Brazil, including the escalating threat of antimicrobial resistance (AMR), the urgent need to address the impact of climate change on...

WHO South-East Asia Region SEARO

:: 5 September 2024 *News release*

[**Regional Director's Remarks at the Opening Session of the Seventeenth Meeting of the Subcommittee on Policy and Programme Development and Management \(SPPDM\)**](#)

:: 4 September 2024 *News release*

[**Regional Director's Opening Address at the 8th Meeting of the Asia-Pacific Parliamentary Forum for Global Health, Port Villa, Vanuatu**](#)

WHO European Region EURO

No new digest content identified.

WHO Eastern Mediterranean Region EMRO

:: [**Call for Experts: Eastern Mediterranean Research Ethics Review Committee \(EM-RERC\)**](#)

Deadline: 16 September 2024

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

[**Public Health Situation Analysis: Sudan conflict \(01 September 2024\)**](#)

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

[**4 September 2024 | Influenza A\(H1N1\) variant virus - Viet Nam**](#)

[**2 September 2024 | Avian Influenza A\(H5N1\) - Cambodia**](#)

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 99, No. 36, pp. 457–496 6 September 2024

PDF: <https://iris.who.int/bitstream/handle/10665/378642/WER9935-eng-fre.pdf>

:: Cabo Verde certified as malaria-free

:: Cholera, 2023

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected

6 September 2024

[**Consumption and Rational use of Antimicrobials in South-East Asia Region, 2024**](#)

4 September 2024

[WHO SEAR 18th Epidemiological Bulletin 2024](#)

3 September 2024

[Target product profile for a diagnostic test to confirm visceral leishmaniasis](#)

3 September 2024

[Guidance on wastewater and solid waste management for manufacturing of antibiotics](#)

.....
.....

USA – HHS, FDA, CDC

HHS

News

No new digest content identified.

FDA

Press Announcements

[FDA Roundup: September 6, 2024](#)

...Today, the FDA issued a draft guidance "[Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle](#)". This guidance, when finalized, is intended to provide recommendations on how patient preference information might be collected and shared with the FDA and potentially be considered in FDA decision-making processes. It also provides recommendations on designing patient preference studies that may provide reliable scientific evidence. On Oct. 15, 2024, the FDA will [host a webinar](#) for industry and other parties interested in learning more about the draft guidance. Please submit comments under docket number FDA-2015-D-1580 at www.regulations.gov by Dec. 5, 2024, to ensure the FDA considers comments before it begins work on the final version of the guidance...

FDA VRBPAC

Advisory Committee Calendar

[Vaccines and Related Biological Products Advisory Committee September 20, 2024 Meeting Announcement - 09/20/2024](#)

CDC/ACIP [U.S.] [to 07 Sep 2024]

<http://www.cdc.gov/media/index.html>

Latest News

[CDC Confirms Human H5 Bird Flu Case in Missouri](#)

CDC has confirmed a human case of avian influenza A(H5) ("H5 bird flu") reported by the state of Missouri. Sep 6, 2024

ACIP Meetings

Next ACIP Meeting

October 23-24, 2024

MMWR Weekly

<https://www.cdc.gov/mmwr/index2023.html>

September 5, 2024 / No. 35

[PDF of this issue](#)

[Contact Tracing for Mpox Clade II Cases Associated with Air Travel — United States, July 2021–August 2022](#)

.....
.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 September 2024

EMA recommends measures to minimise serious outcomes of known side effect with painkiller metamizole

6 September 2024

Harnessing AI in medicines regulation: use of large language models (LLMs)

Guiding principles set out how EU medicine regulators can use LLMs in a safe, responsible and effective manner

5 September 2024

[Guiding principles on the use of large language models in regulatory science and for medicines regulatory activities](#)

English (EN) (198.5 KB - PDF)

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

Surveillance and monitoring

Communicable disease threats report, 31 August - 6 September 2024, week 36

6 Sep 2024

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 31 August - 6 September 2024 and includes updates on mpox, West Nile virus, SARS-CoV-2 variants, influenza A(H5N1), human cases of swine influenza A(H1N1), an overview of respiratory virus epidemiology in the EU/EEA, and mass gathering monitoring for the Olympic and Paralympic Games.

News

World Sexual Health Day 2024 - Actions needed to limit the spread of sexually transmitted infections in Europe

4 Sep 2024

News

Epidemiological update – Week 35/2024: Mpox due to monkeypox virus clade I

2 Sep 2024

.....
.....

Africa CDC [to 07 Sep 2024]

<https://africacdc.org/>

Press Releases, Statements [Selected]

African CDC and WHO Launch Joint Continental Plan to Scale Up Mpox Outbreak Response

6 September 2024

Press Releases

La RDC réceptionne les premiers vaccins contre la Mpox

5 September 2024

Press Releases

Joint Press Release: The Democratic Republic of Congo receives first Mpox vaccines

5 September 2024

.....
.....

China CDC

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 07 Sep 2024]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 07 Sep 2024]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (6)

2024-09-06 / No. 36

[PDF of this issue](#)

- [Vital Surveillances: Two Peaks of Seasonal Influenza Epidemics — China, 2023](#)
- [Vital Surveillances: Rodent Ecology and Etiological Investigation in China: Results from Vector Biology Surveillance — Shandong Province, China, 2012–2022](#)
- [Preplanned Studies: Comparison of Three Influenza Surveillance Data Sources for Timely Detection of Epidemic Onset — Chengdu City, Sichuan Province and Beijing Municipality, China, 2017–2023](#)
- **[Review: A Systematic Review of the Definition, Measurement, and Associated Factors of Pandemic Fatigue](#)**
- [Review: Socioeconomic Impact and Response Strategies to the Multifaceted Respiratory Illness Outbreak in Northern China: Beyond Influenza A and Mycoplasma Pneumoniae](#)

Review: A Systematic Review of the Definition, Measurement, and Associated Factors of Pandemic Fatigue

[Ruohan Chen](#), et al.

Abstract

The rapid emergence and widespread transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have prompted governments worldwide to enact policies and measures to manage the virus's spread. These interventions have substantially contributed to controlling disease transmission. However, they have also significantly disrupted daily life, leading to increased public fatigue and resistance to sustained control measures, a phenomenon known as pandemic fatigue. To develop a comprehensive understanding of pandemic fatigue, this review systematically explores the concept and identifies quantitative indicators for measuring it. We reviewed studies on pandemic fatigue across various countries, summarized the contributing factors, and analyzed its impact on personal protective

behaviors. Our findings indicate that the enforcement of health measures significantly influences the onset of pandemic fatigue, while individual perceptions of risk can negatively affect personal protective behaviors, creating a feedback loop with increasing fatigue. These results underscore the importance of considering the current severity of the pandemic and individual decision-making processes in the implementation of interventions. Enhancing our understanding of pandemic fatigue is essential for developing effective policy responses in preparation for future potential epidemics...

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)
:: [*WHO*](#)
:: [*Organization Announcements*](#)
:: [*Journal Watch*](#)
:: [*Pre-Print Servers*](#)

.....
.....

Organization Announcements

Paul G. Allen Frontiers Group [to 07 Sep 2024]

<https://alleninstitute.org/news-press/>

News

[Allen Institute for Cell Science and New York Stem Cell Foundation join forces to advance inclusive cellular biology](#)

09.04.2024

Partnership combines advanced cellular tagging with ethnically diverse stem cell lines, addressing critical gaps in biomedical research

BMGF - Gates Foundation [to 07 Sep 2024]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 07 Sep 2024]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications

No new digest content identified.

CARB-X [to 07 Sep 2024]

<https://carb-x.org/>

News

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 07 Sep 2024]

<http://cepi.net/>

CEPI News

[CEPI's CEO Richard Hatchett receives honorary doctorate from the University of Oslo](#)

2 Sep 2024

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 07 Sep 2024]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 07 Sep 2024]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 07 Sep 2024]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [to 07 Sep 2024]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [to 07 Sep 2024]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 07 Sep 2024]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Evidence Aid [to 07 Sep 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

Resources [Selected]

Prevention and control of Infectious diseases after disasters caused by natural hazards

Added September 3, 2024

Fondation Merieux [to 07 Sep 2024]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 07 Sep 2024]

<https://www.gavi.org/>

Press Releases

No new digest content identified.

GE2P2 Global Foundation [to 07 Sep 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – June 2024](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 29 August – Issue 22](#)

GHIT Fund [to 07 Sep 2024]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 07 Sep 2024]

<https://www.theglobalfund.org/en/news/>

News Releases

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 07 Sep 2024]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 07 Sep 2024]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 07 Sep 2024]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 07 Sep 2024]

<https://www.humanimmunomeproject.org/>

News

No new digest content identified.

IAVI [to 07 Sep 2024]

<https://www.iavi.org/>

News, Features

No new digest content identified.

INSERM [to 07 Sep 2024]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 07 Sep 2024]

<https://www.ich.org/>

News/Pubs/Press Releases [Selective]

No new digest content identified.

ICRC [to 07 Sep 2024]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 07 Sep 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

Press release _05/09/2024

Amman Declaration 2024: A unified call for future-ready humanitarian action in the MENA region

Institut Pasteur [to 07 Sep 2024]

<https://www.pasteur.fr/en/press-area>

Press Documents

Press Info 03.09.2024

First sustained remission of HIV infection following a bone marrow transplant in the absence of protective mutation

Case of Geneva patient presented in the prestigious scientific journal Nature Medicine.

ISC / International Science Council [to 07 Sep 2024]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

No new digest content identified.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

No new digest content identified.

IVAC [to 07 Sep 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 07 Sep 2024]

<http://www.ivi.int/>

IVI News & Announcements

IVI's 23rd International Vaccinology Course connects Seoul, Stockholm, and Kigali for an intensive course on the science of vaccines and vaccination

September 2, 2024,

Johns Hopkins Center for Health Security [to 07 Sep 2024]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

September 4, 2024:

Johns Hopkins Center for Health Security launches Gene Synthesis Screening Information Hub

Today, the Center for Health Security announces the Gene Synthesis Screening Information Hub, a new online platform dedicated to helping nucleic acid synthesis providers, manufacturers, and

customers adhere to a new federal Framework aimed at preventing intentional misuse of synthetic nucleic acids and supporting safe scientific research practices in the United States...

MSF/Médecins Sans Frontières [to 07 Sep 2024]

<http://www.msf.org/>

Latest [Selected Announcements]

Haiti

[Rapid and safe access to medical care must be guaranteed in Port-au-Prince](#)

Press Release 6 Sep 2024

Palestine

[Access to medical care at risk in West Bank as Israeli incursions intensify](#)

Press Release 5 Sep 2024

Democratic Republic of Congo

[Mpox in eastern DRC is just another challenge amid torrent of problems](#)

Voices from the Field 4 Sep 2024

National Academy of Medicine - USA [to 07 Sep 2024]

<https://nam.edu/programs/>

News [Selected]

[National Academy of Medicine Announces 10 Emerging Leaders in Health and Medicine](#)

September 4, 2024

The National Academy of Medicine (NAM) has selected the 2024 class of Emerging Leaders in Health and Medicine Scholars, a group of early- to mid-career professionals from a wide range [...]

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 07 Sep 2024]

<https://www.nationalacademies.org/newsroom?>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 07 Sep 2024]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

[September 12-13, 2024](#) - Agenda

NIH [to 07 Sep 2024]

<http://www.nih.gov/>

News Releases

No new digest content identified.

PATH [to 07 Sep 2024]

<https://www.path.org/media-center/>

Newsroom

No new digest content identified.

Sabin Vaccine Institute [to 07 Sep 2024]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNICEF [to 07 Sep 2024]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

Statement 04 September 2024

Statement by UNICEF Regional Director for the Middle East and North Africa, Adele Khodr, on the completion of the first phase of the polio vaccination campaign in the Gaza Strip

AMMAN, 4 SEPTEMBER 2024 – “The past three days have brought a rare bright spot amid the disastrous conflict in the Gaza Strip. “After almost a year of families experiencing horrors no man, woman or child should ever have to endure, this week we saw what can be achieved with, simply, will. “For at least a quarter of a century, there were no cases...

Press release 02 September 2024

Nearly one million children and pregnant women in the Democratic People's Republic of Korea to receive life-saving routine vaccines

BANGKOK, 3 September 2024 – More than 800,000 children and 120,000 pregnant women will be vaccinated in a nationwide campaign launched on Monday by the Government of the Democratic People's Republic of Korea (DPRK) with UNICEF support. The vaccination campaign will reach children and pregnant women in all 210 counties who have missed out on life...

Unitaid [to 07 Sep 2024]

<https://unitaid.org/>

Featured News

No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 07 Sep 2024]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 07 Sep 2024]

<https://www.vaccineacceptance.org/>

Announcements, Blog

No new digest content identified.

Vaccine Confidence Project [to 07 Sep 2024]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 07 Sep 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

Vaccine Update Newsletter August 2024

Wellcome Trust [to 07 Sep 2024]

<https://wellcome.org/news/all>

News, Opinion, Reports

Explainer

Author - Simge Eva Dogan

Explained: the history of progress in tackling antimicrobial resistance

3 September 2024

The Wistar Institute [to 07 Sep 2024]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

World Bank [to 07 Sep 2024]

<http://www.worldbank.org/en/news/all>

All News [Selected]

Sri Lanka Pandemic Preparedness Assessment (2020-2023)

The Sri Lanka Pandemic Preparedness Assessment, aimed to help the government optimize health investments and improve preparedness for future pandemics, especially considering the needs of a rapidly aging...

Date: September 05, 2024 Type: Feature Story

WFPHA: World Federation of Public Health Associations [to 07 Sep 2024]

<https://www.wfpha.org/>

Blog, Events

No new digest announcements identified.

World Medical Association [WMA] [to 07 Sep 2024]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest announcements identified.

World Organisation for Animal Health [OIE] [to 07 Sep 2024]

<https://www.oie.int/>

Press Releases, Statements

No new digest announcements identified.

.....

.....

ARM [Alliance for Regenerative Medicine] [to 07 Sep 2024]

<https://alliancerm.org/press-releases/>

Selected Press Releases
No new digest content identified.

BIO [to 07 Sep 2024]
<https://www.bio.org/press-releases>
Press Releases
No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 07 Sep 2024]
<http://www.dcvmn.org/>
News; Upcoming events
[ANNUAL GENERAL MEETING 2024](#)
October 16 - 18, 2024 São Paulo, Brazil

ICBA – International Council of Biotechnology Associations [to 07 Sep 2024]
<https://internationalbiotech.org/news/>
News
No new digest announcements identified.

IFPMA [to 07 Sep 2024]
<https://ifpma.org/>
News, Statements [Selected]
No new digest announcements identified.

International Alliance of Patients' Organizations – IAPO [to 07 Sep 2024]
<https://www.iapo.org.uk/news>
Press and media [Selected]
[IAPO statements at the 74th session of the WHO Regional Committee for Africa](#)
Tuesday, 3 September 2024

International Generic and Biosimilar Medicines Association [IGBA]
<https://www.igbamedicines.org/>
News
No new digest announcements identified.

PhRMA [to 07 Sep 2024]
<http://www.phrma.org/>
Press Releases
No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases - No new digest announcements identified.

Bavarian Nordic

Latest News

September 05, 2024

First Doses of Bavarian Nordic's Mpox Vaccine Now Arriving in the Democratic Republic of Congo

- Vaccine donations from the European Commission, the U.S. government and Bavarian Nordic are now entering the DRC, the epicenter of the mpox outbreak
- More than 250,000 doses to arrive over the next week, marking a crucial turning point in the combat against mpox in Africa

Bharat Biotech

Press Releases - No new digest announcements identified

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified

Biological E

News - No new digest announcements identified

BioNTech

Press Releases - No new digest announcements identified

Boehringer

Press Releases - No new digest announcements identified

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified.

Cinnagen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

Curevac - No new digest announcements identified

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

03 Sep 2024

GSK aims to redefine the future of respiratory medicine at the European Respiratory Society International Congress

- 56 abstracts to advance scientific understanding and support GSK's ambition to improve the lives of millions of people with respiratory conditions

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

Janssen/JNJ

Press Releases - No new digest announcements identified.

Merck

News releases - No new digest announcements identified

Moderna

Press Releases

September 5, 2024

[EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1](#)

September 3, 2024

[Moderna Receives Medicines And Healthcare Products Regulatory Agency \(MHRA\) UK Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1](#)

September 2, 2024

[Taiwan Food & Drug Administration Approves Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1](#)

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified.

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases - No new digest announcements identified

SK Biosciences

Press Releases

SK bioscience and CEPI Deepen Partnership for Pandemic Prevention, Preparedness and Response

-The Coalition for Epidemic Preparedness Innovations (CEPI) visited Korea to discuss collaboration w...
2024.08.30

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases

September 3, 2024

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Vector State Research Centre of Virology and Biotechnology

Home - [Website not responding [404 error]]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 15, 2023 Issue 3

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 26, Number 9: E665-744

<https://journalofethics.ama-assn.org/issue/nonhuman-animal-research>

Nonhuman Animal Research

Nonhuman animals have long been and continue to be routinely used in biomedical and behavioral research to promote human health. When SARS-CoV2 infections triggered a race to develop and scale global access to vaccines in 2019, two key innovations happened to the supply chain of nonhuman animals created, raised, and used for science: (1) experiments and trials regarded as essential were prioritized and (2) governments and researchers shortened vaccine production timelines. Clinical and public health urgency concentrated and acutely focused demand for live mammals—especially ferrets, guinea pigs, hamsters, mice, nonhuman primates, pigs, and rats—in ways that also intensified demand for efficient protocol designs and streamlined methods of human vaccine research and development. Reasonable people can still disagree about when, why, and how nonhuman animals should be sacrificed for human health, but we now know that human health endeavors, specifically vaccine development, flourish even when we sanction fewer nonhuman animals' cultivation and deaths for science. This theme issue investigates what this revelation from the pandemic means from clinical, ethical, legal, and policy standpoints for the future of human-centered research.

American Journal of Human Genetics

Sep 05, 2024 Volume 111 Issue 9 p1797-2070

<https://www.cell.com/ajhg/current>

This Month in The Journal

Alyson B. Barnes, Kylee L. Spencer

Proteogenomics draws on the fields of genomics, transcriptomics, and proteomics to discern how genetic variation influences the set of proteins produced by a cell with the goal of elucidating how this relates to disease risk. Although colocalization approaches can be used to identify variants that are tied to both splicing and disease, the limitations of short-read RNA sequencing have often prevented determining which protein isoform or group of isoforms specifically mediates risk. In this issue, Abood et al.

Year in Review

All of Us Research Program year in review: 2023–2024

Elyse Kozlowski, et al.

The All of Us Research Program aims to advance precision medicine by enrolling and retaining one million individuals throughout the United States with a focus on communities who have been historically underrepresented in biomedical research. Data from over 400,000 participants comes from multiple sources, including whole genome sequences, electronic health records (EHRs), wearable devices, physical measures, and surveys, and is available via the cloud-based Researcher Workbench (<https://www.researchallofus.org/data-tools/workbench/>).

American Journal of Infection Control

September 2024 Volume 52 Issue 9 p985-1104

<http://www.ajicjournal.org/current>

Major Articles

Utilizing natural language processing and large language models in the diagnosis and prediction of infectious diseases: A systematic review

Mahmud Omar, et al.

Published online: April 05, 2024

p992-1001

Did the health care vaccine mandate work? An evaluation of the impact of the COVID-19 vaccine mandate on vaccine uptake and infection risk in a large cohort of Canadian health care workers

Arnold I. Okpani, et al.

Published online: May 14, 2024

p1065-1072

State of the Science Reviews

Influenza vaccination and COVID-19 infection risk and disease severity: A systematic review and multilevel meta-analysis of prospective studies

Marco Del Riccio, et al.

Published online: May 18, 2024

p1091-1098

Open Access

American Journal of Preventive Medicine

September 2024 Volume 67 Issue 3 p319-476

<https://www.ajpmonline.org/current>

[New issue; No digest content identified]

American Journal of Public Health

October 2024 114(109)

<http://ajph.aphapublications.org/toc/ajph/current>

PERSPECTIVES

The Dire Need for Surveillance of Vaccine Hesitancy in the United States

David M. Higgins MD, MPH and Sean T. O'Leary MD, MPH

114(10), pp. 983–985

HEALTH MONITORING

Mortality Surveillance for the COVID-19 Pandemic: Review of the Centers for Disease Control and Prevention's Multiple System Strategy

Diba Khan PhD, MS, Meeyoung Park MPH, Peter Grillo BS, Lauren Rossen PhD, MS, B. Casey Lyons MPH, Sarah David MPH, Matthew D. Ritchey PT, DPT, MPH, Farida B. Ahmad MPH, A. D. McNaghten PhD, MS, Adi V. Gundlapalli MD, PhD and Amitabh B. Suthar PharmD, MPH

American Journal of Tropical Medicine and Hygiene

Volume 111 (2024): Issue 3 (Sep 2024)

<https://www.ajtmh.org/view/journals/tpmd/111/3/tpmd.111.issue-3.xml>

Editorial

Tropical Diseases in the United States: Beyond Poverty – Advancing an Ecological Framework in Tropical Medicine

Michael E. DeWitt and John W. Sanders

DOI: <https://doi.org/10.4269/ajtmh.24-0251>

Articles

Modeling the Impact of Proactive Community Case Management on Reducing Confirmed Malaria Cases in Sub-Saharan African Countries

Yifan Wang, et al.

Article Category: Research Article

DOI: <https://doi.org/10.4269/ajtmh.23-0844>

Healthcare Providers' and Frontline Workers' Experiences of an Ebola Vaccine Trial in the Boende Health District of the Democratic Republic of the Congo

Trésor Zola Matuvanga, et al.

Article Category: Research Article

DOI: <https://doi.org/10.4269/ajtmh.23-0581>

Annals of Internal Medicine

August 2024 Volume 177, Issue 8

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 334 September 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/334/suppl/C>

[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 07 Sep 2024)

HPV vaccination strategy for 14-year-old females and economic returns for cervical cancer prevention in Wuxi City, China: a cost effectiveness analysis

Authors: Jingfeng Jiang, Fanqi Zhao, Xiang Hong and Xuwen Wang

Content type: Research 5 September 2024

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 07 Sep 2024)

The transformation of Jordan's healthcare system in an area of conflict

The Jordanian healthcare system has evolved over the past decades expanding its services, technological, and educational resources. A comprehensive view of this system is lacking. The objective of this report ...

Authors: Ahmad Tamimi, Mousa Al-Abbadi, Iskandar Tamimi, Malik Juweid, Muayyad Ahmad and Faleh Tamimi

Citation: *BMC Health Services Research* 2024 24:1033

Content type: Research Published on: 6 September 2024

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 07 Sep 2024)

Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain

Respiratory syncytial virus (RSV) is associated with substantial morbidity among infants. This study modelled the potential public health and economic impact of nirsevimab, a long-acting monoclonal antibody, a...

Authors: Ruth Gil-Prieto, Jaime Jesus Pérez, Georgina Drago, Alexia Kieffer, Julie Roiz, Paulina Kazmierska, Aditya Sardesai, Solène de Boisvilliers, Juan Luis López-Belmonte, Matthieu Beuvelet and Javier Alvarez Aldean

Citation: BMC Infectious Diseases 2024 24:924

Content type: Research Published on: 6 September 2024

Insights into maternal pertussis vaccination counselling: a qualitative study on perspectives and experiences among midwives and gynaecologists in the Netherlands

Healthcare professionals (HCPs) play a significant role in the decision-making process of pregnant women on maternal vaccinations. Whereas a high proportion of HCPs discuss maternal vaccinations with pregnant ...

Authors: Veja Widdershoven, Eveline C.H. van Eerd, Marije Pfeyffer, Liesse M.L. Vanderhoven, Amanja Verhaegh-Haasnoot, Rianne P. Reijs and Christian J.P.A. Hoebe

Citation: BMC Infectious Diseases 2024 24:903

Content type: Research Published on: 2 September 2024

Factors influencing the third COVID-19 vaccine booster dose acceptance among older adults in northern Thailand

Coronavirus disease 2019 (COVID-19) causes more deaths in older adults than in younger adults. Older adults are a vulnerable group with a high need for coronavirus vaccines to decrease the severity of the disease...

Authors: Archin Songthap, Kanamas Sesang, Chanikan Ratchaphan, Thanachaporn Luangkhan and Phattaraporn Jenjob

Citation: BMC Infectious Diseases 2024 24:897

Content type: Research Published on: 2 September 2024

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 07 Sep 2024)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 07 Sep 2024)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 07 Sep 2024)

[No new digest content identified]

BMC Public Health

<http://bmcpublihealth.biomedcentral.com/articles>

(Accessed 07 Sep 2024)

[Prevalence, spatial distribution and determinants of complete childhood pneumococcal conjugate vaccination in Ethiopia: spatial and multilevel analyses](#)

Pneumococcal disease is a serious global public health concern. The primary causative agent of severe illnesses such as pneumonia, meningitis, acute otitis media, and bacteremia is the pneumococcus bacterium. ...

Authors: Tadesse Tarik Tamir, Bewuketu Terefe, Mulugeta Wassie, Belayneh Shetie Workneh and Alebachew Ferede Zegeye

Citation: *BMC Public Health* 2024 24:2433

Content type: Research Published on: 6 September 2024

[Factors associated with full COVID-19 vaccination among persons living with diabetes mellitus in Uganda–A cross-sectional study](#)

Diabetes mellitus (DM) is associated with severe outcomes of coronavirus disease (COVID-19), including death. COVID-19 vaccination is crucial for preventing infection and severe disease in the general populati...

Authors: Umar Senoga, David Guwatudde, John Bosco Isunju and Kevin Ouma Ojiambo

Citation: *BMC Public Health* 2024 24:2422

Content type: Research Published on: 5 September 2024

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 07 Sep 2024)

[No new digest content identified]

BMJ Evidence-Based Medicine

August 2024 - Volume 29 - 4

<https://ebm.bmj.com/content/29/4>

[Reviewed earlier]

BMJ Global Health

September 2024 - Volume 9 - 9

<https://gh.bmj.com/content/9/9>

Original research

[The global health and economic value of COVID-19 vaccination](#) (7 September, 2024)

JP Sevilla, Daria Burnes, Joseph S Knee, Manuela Di Fusco, Moe H Kyaw, Jingyan Yang, Jennifer L Nguyen, David E Bloom

We provide the first estimates of the broad value of CV incorporating GDP, QALY and direct and indirect cost impacts. Through December 2021, CV produced significant health and economic value, represented strong value for money and produced significant macroeconomic benefits that should be considered in vaccine evaluation.

Bulletin of the Atomic Scientists

September 2024

<https://thebulletin.org/magazine/2024-09/>

Introduction: Securing elections, democracy, and the information ecosystem in a critical political year

By John Mecklin, Dan Drollette Jr

This election will take place in a landscape full of threats to many of the world's democracies. This issue of the Bulletin strives to help citizens and their public officials reduce those threats and preserve representative governance.

Bulletin of the World Health Organization

Volume 102(9); 2024 Sep 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/469680/>

Editorials

Policy dimensions of global wastewater surveillance

Megan B Diamond, Toni Whistler, Karina Rando, Chioma Nwachukwu, Mukhlid Yousif
Bull World Health Organ. 2024 Sep 1; 102(9): 622–622A. Published online 2024 Sep 1.
doi: 10.2471/BLT.24.292245
PMCID: PMC11362689

Wastewater surveillance to track influenza viruses

Leshan Xiu, Kun Yin
Bull World Health Organ. 2024 Sep 1; 102(9): 623–623A. Published online 2024 Sep 1.
doi: 10.2471/BLT.24.292285
PMCID: PMC11362693

Lessons from the Field

COVID-19 vaccination campaigns in fragile and conflict-affected settings, Somalia

Muhammad Farid, Abdulrazak Ibrahim, Hamayoun Mohammad, Quamrul Hassan, Mohamed Abdullahi Omar, Mohamed Abdulrahman Ismael, Abdifatah Mohamed Shidane, Mohamed Farah Mohamud, Mukhtar Shube, Mustafe Awil Jama, Patience Musanhu, Rehan Hafiz, Sk Md Mamunur Rahman Malik
Bull World Health Organ. 2024 Sep 1; 102(9): 674–680. Published online 2024 Jul 11.
doi: 10.2471/BLT.23.291105
PMCID: PMC11362698

... This strategy included careful microplanning, better targeting of populations and providing people-centred vaccination services close to their homes. These services were combined with childhood vaccination and basic health-care provision using the existing polio network and community health workers. Additionally, a digital tool for recording COVID-19 vaccination data and a mobile phone-based electronic registration system were introduced...

Successful roll-out of adult vaccination is achievable even in a fragile and conflict-affected setting through implementation of a tailored contextualized approach. Key factors include good microplanning, use of digital tools, better population-targeting, bundling vaccines together and delivering vaccination services close to people's homes.

Cell

Aug 22, 2024 Volume 187 Issue 17 p4431-4812

<https://www.cell.com/cell/current>

[Reviewed earlier]

Child Care, Health and Development

Volume 50, Issue 5 September 2024
<https://onlinelibrary.wiley.com/toc/13652214/current>
[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 116, Issue 3 Pages: 479-874 September 2024
<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

Issue Focus: Getting the Dosage Right

Editorial Free Access

[Getting the Dosage Right: A Vital Role for Clinical Pharmacology in the Era of Precision Medicine](#)

Iris K. Minichmayr, Mohamad Shebley, Piet H. van der Graaf, Karthik Venkatakrishnan

Pages: 491-496

First Published: 20 August 2024

Clinical Therapeutics

August 2024 Volume 46 Issue 8 p595-660

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 21 Issue 4, August 2024

<https://journals.sagepub.com/toc/ctja/21/4>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 07 Sep 2024]

[No new digest content identified]

Contemporary Clinical Trials

Volume 144 September 2024

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/144/suppl/C>

[New issue; No digest content identified]

The CRISPR Journal

Volume 7, Issue 4 / August 2024

<https://www.liebertpub.com/toc/crispr/7/4>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 11, Issue 3-4 December 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-3>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 8 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

August 2024 - Volume 37 - Issue 4

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 07 Sep 2024]

[No new digest content identified]

Developing World Bioethics

Volume 24, Issue 3 Pages: 135-261 September 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

FEATURE ARTICLE Open Access

[Ethical, legal, and social implications in research biobanking: A checklist for navigating complexity](#)

Olga Tzortzatou-Nanopoulou, Kaya Akyüz, Melanie Goisauf, Łukasz Kozera, Signe Mežinska, Michaela Th. Mayrhofer, Santa Slokenberga, Jane Reichel, Talishiea Croxton, Alexandra Ziaka, Marina Makri

Pages: 139-150

First Published: 10 July 2023

Abstract

Biobanks' activity is based not only on securing the technology of collecting and storing human biospecimen, but also on preparing formal documentation that will enable its safe use for scientific research. In that context, the issue of informed consent, the reporting of incidental findings and the use of Transfer Agreements remain a vast challenge. This paper aims to offer first-hand tangible solutions on those issues in the context of collaborative and transnational biobanking research. It presents a four-step checklist aiming to facilitate researchers on their compliance with applicable legal and ethical guidelines, when designing their studies, when recruiting participants, when handling samples and data, and when communicating research results and incidental findings. Although the paper reflects the outcomes of the H2020 B3Africa project and examines the transfers from and to the EU as a case study, it presents a global checklist that can be used beyond the EU.

Development in Practice

Volume 34, Issue 6, 2024

<https://www.tandfonline.com/toc/cdip20/34/6>

[New issue; No digest content identified]

Development Policy Review

Volume 42, Issue 5 September 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

[New issue; No digest content identified]

Disaster Medicine and Public Health Preparedness

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 48, Issue 3 July 2024

<https://onlinelibrary.wiley.com/toc/14677717/2024/48/3>

[Reviewed earlier]

EMBO Reports

Volume 25 Issue 8 9 August 2024

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 30, Number 7—July 2024

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 47 June 2024

<https://www.sciencedirect.com/journal/epidemics/vol/47/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 46, Issue 4 Pages: 1-51 July–August 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

Research with refugee populations Ethical considerations for crowdsourced research

[Reviewed earlier]

Ethics & International Affairs

Volume 37 - Issue 4 - Winter 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 34, Issue 4, August 2024

<https://academic.oup.com/eurpub/issue/34/4>

[Reviewed earlier]

Expert Review of Vaccines

Vol 23 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

July/August 2024 Volume 103, Number 4

<https://www.foreignaffairs.com/issues/2023/103/4>

[Reviewed earlier]

Forum for Development Studies

Volume 51, 2024 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genetics in Medicines

Volume 26, Issue 9 September 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/9>

[New issue; No digest content identified]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 07 Sep 2024]

[No new digest content identified]

Global Health Action

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 4 August 27, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 07 Sep 2024]

Article

European Union: General Court Rules European Commission Must Grant Wider Access to COVID-19 Vaccine Purchase Agreements

On July 17, 2024, the General Court of the European Union (EU) held that under an EU freedom of information law, the European Commission (Commission) failed to give sufficient public access to COVID-19 vaccine purchase agreements. Six members of the European Parliament (MEPs) had brought an action for annulment before the court and requested access ... Continue reading "European Union: General Court Rules European..."

Contributor: Gesley, Jenny

Date: 2024-09-04

Global Public Health

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rqph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 07 Sep 2024]

[No new digest content identified]

Health and Human Rights

Volume 26, Issue 1, June 2024

<https://www.hhrjournal.org/volume-26-issue-1-june-2024/>

SPECIAL SECTION – COMMEMORATING 30 YEARS

[Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 2 - April 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 39, Issue 7, August 2024

<https://academic.oup.com/heapol/issue/39/7>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>
[Accessed 07 Sep 2024]
[No new digest content identified]

Human Gene Therapy

Volume 35, Issue 15-16 / August 2024
<https://www.liebertpub.com/toc/hum/35/15-16>
[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>
Featured Publications
[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 20 Issue 1, 2024
<https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList>
Selected Content
[Reviewed earlier]

Immunity

Aug 13, 2024 Volume 57 Issue 8 p1713-1994
<https://www.cell.com/immunity/current>
[New issue; No digest content identified]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>
[Accessed 07 Sep 2024]
[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>
[Accessed 07 Sep 2024]
[No new digest content identified]

International Health

Volume 16, Issue 5, September 2024
<https://academic.oup.com/inthealth/issue/16/5>
Editor's Choice
[Global knowledge and attitudes towards mpox \(monkeypox\) among healthcare workers: a systematic review and meta-analysis](#)
Abdolreza Sotoodeh Jahromi and others
International Health, Volume 16, Issue 5, September 2024, Pages 487–498,
<https://doi.org/10.1093/inthealth/ihad094>

Commentary

Is the African Vaccine Manufacturing Accelerator a decoupling mechanism?

Abiodun E Awosusi

International Health, Volume 16, Issue 5, September 2024, Pages 568–570,

<https://doi.org/10.1093/inthealth/ihae032>

This article explores how the African Vaccine Manufacturing Accelerator can support the sustainable production of vaccines in Africa. It highlights the value of the accelerator in relation to the Regional Vaccine Manufacturing Collaborative. The author proposes that this novel financing instrument should be well-designed and implemented in line with the targets of the Partnerships for African Vaccine Manufacturing. It should not be a decoupling tool to appease the institutional environment of the global vaccine market, but a sustainable demonstration of the goodwill and commitment of political and technical leaders to ensure equitable access to routine and epidemic-related vaccines in Africa.

International Human Rights Law Review

Volume 13 (2024): Issue 1 (Jun 2024):

<https://brill.com/view/journals/hrlr/13/1/hrlr.13.issue-1.xml>

Special Issue on Inter-State Communications

Table of Contents

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 11 No. 7 (2024): July 2024

<https://www.ijcmph.com/index.php/ijcmph/issue/view/114>

[Reviewed earlier]

International Journal of Epidemiology

Volume 53, Issue 3, June 2024

<https://academic.oup.com/ije/issue/53/3>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 17 Issue 3 2024

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/3>

Table of contents

[Reviewed earlier]

JAMA

September 3, 2024, Vol 332, No. 9, Pages 687-768

<https://jamanetwork.com/journals/jama/currentissue>

Viewpoint

The Double-Edged Sword of Extremely High Prices for Gene Therapies in Sickle Cell Disease

Edward R. Scheffer Cliff, MBBS, MPH; Frazer A. Tessema, BA

JAMA. 2024;332(9):703-704. doi:10.1001/jama.2024.11703

This Viewpoint discusses the high cost of new gene therapies for sickle cell disease, the challenges these costs pose for health care access, and new policy approaches to ensure fair reimbursement for

payers and manufacturers without further increasing health care costs or barriers to access for underserved populations.

Abstract

With the recent US Food and Drug Administration and European Medicines Agency approvals of gene therapy for sickle cell disease, exagamglogene autotemcel (exa-cel) (Casgevy, Vertex Pharmaceuticals and CRISPR Therapeutics), the transformational gene-editing technology CRISPR-Cas9 was officially converted into an approved therapeutic modality just 11 years after it was discovered.¹ This treatment, along with lovotibeglogene autotemcel (lovo-cel) (Lyfgenia, bluebird bio), a lentiviral vector therapy, offer new avenues for treating—and perhaps even offering functional cures for—sickle cell disease, a debilitating congenital disease that disproportionately affects Black patients and other patients facing health disparities.

JAMA Health Forum

September 2024, Vol 5, No. 9

<https://jamanetwork.com/journals/jama-health-forum/issue>

[New issue; No digest content identified]

JAMA Pediatrics

September 2024, Vol 178, No. 9, Pages 847-956

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

Original Investigation

Disparities in HPV Vaccination Among Adolescents by Health Care Facility Type

Mrudula Nair, BDS, MPH; Joël Fokom Domgue, MD, MPH; Christine L. M. Joseph, PhD; et al.

JAMA Pediatr. 2024;178(9):932-939. doi:10.1001/jamapediatrics.2024.2383

This cross-sectional study examines the association of health care facility type with clinician recommendations for and adolescent uptake of human papillomavirus (HPV) vaccination in the US.

JBIC Evidence Synthesis

August 2024 - Volume 22 - Issue 8

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

Protocols

Economic evaluations of neglected tropical disease interventions in low- and middle-income countries: a systematic review protocol

Mahapatra, Biswajit; Mukherjee, Nirmalya; Khatoon, Sajda; More

JBIC Evidence Synthesis. 22(8):1582-1593, August 2024.

Journal of Adolescent Health

September 2024 Volume 75 Issue 3 p375-52

<https://www.jahonline.org/current>

Review Article

Unifying Public Health Surveillance: A Scoping Review of Global Use of the Youth Risk Behavior Survey

P'Ashe Jones, et al.

Published online: May 14, 2024

p383-391 Open Access

Original Articles

Research Ethics of Involving Adolescents in Health Research Studies: Perspectives From Australia

Neha Faruqui, et al.

Published online: July 13, 2024

p502-507 Open Access

Adolescent participation in health research studies is critical yet complex given the lack of clarity around issues such as consent. This study aimed to understand how those conducting research in Australia navigate research ethics in health research involving adolescents, through qualitative interviews.

Journal of Artificial Intelligence Research

Vol. 80 (2024)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 49, Issue 4 August 2024

<https://link.springer.com/journal/10900/volumes-and-issues/49-4>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[Reviewed earlier]

Journal of Development Economics

Volume 170 September 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/170/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 19 Issue 3, July 2024

<http://journals.sagepub.com/toc/jre/current>

Special Issues in Research and IRB/REC Functioning, Including the use of AI

[Reviewed earlier]

Journal of Epidemiology & Community Health

August 2024 - Volume 78 - 8

<https://jech.bmj.com/content/78/8>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 17, Issue 2 Pages: 237-467 June 2024

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 20, Issue 1 (2024)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 35, Number 3, August 2024

<https://muse.jhu.edu/issue/52935>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 26, Issue 4 August 2024

<https://link.springer.com/journal/10903/volumes-and-issues/26-4>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 22, 2024 _ Issue 3

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of International Development

Volume 36, Issue 5 Pages: 3-2503 July 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

September 2024 - Volume 50 - 9

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 11, Issue 1 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 272 September 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/272/suppl/C>

[New issue; No digest content identified]

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024) Issue 1

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

Journal of Public Health Management & Practice

July/August 2024 - Volume 30 - Issue 4

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 45, issue 3, September 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-3>

[Reviewed earlier]

Journal of the Royal Society – Interface

September 2024 Volume 21 Issue 218

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 31, Issue 6, August 2024

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 98 • Number 6 • June 2024

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Sep 07, 2024 Volume 404 Number 10456 p907-990

<https://www.thelancet.com/journals/lancet/issue/current>

Editorial

[**The structural roots of violence against female health workers**](#)

The Lancet

The Lancet Child & Adolescent Health

Aug 2024 Volume 8 Number 8 p545-610

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Aug 2024 Volume 6 Number 8 e536-e600

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Aug 2024 Volume 12 Number 8 e1214-e1369

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Aug 2024 Volume 24 Number 8 p793-934, e473-e539

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Aug 2024 Volume 9 Number 8 e533-e634

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Aug 2024 Volume 12 Number 8 p575-654, e43-e51

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 28, Issue 7 July 2024

<https://link.springer.com/journal/10995/volumes-and-issues/28-7>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 44 Issue 6, August 2024

<http://mdm.sagepub.com/content/current>

[New issue; No digest content identified]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 102, Issue 2 Pages: 271-516 June 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Molecular Therapy

Aug 07, 2024 Volume 32 Issue 8 p2427-2800

<https://www.cell.com/molecular-therapy/current>
[Reviewed earlier]

Nature

Volume 633 Issue 8028, 5 September 2024

<https://www.nature.com/nature/volumes/633/issues/8028>

Perspective 04 Sept 2024

[Deciphering the impact of genomic variation on function](#)

The Impact of Genomic Variation on Function Consortium is combining single-cell mapping, genomic perturbations and predictive modelling to investigate relationships between human genomic variation, genome function and phenotypes and will provide an open resource to the community.

Jesse M. Engreitz, Heather A. Lawson, Ella K. Samer

Nature Biotechnology

Volume 42 Issue 8, August 2024

<https://www.nature.com/nbt/volumes/42/issues/8>

Review Articles

[Epigenome editing technologies for discovery and medicine](#)

Epigenome editing has versatile applications in biomedical research and disease treatment.

Sean R. McCutcheon, Dahlia Rohm, Charles A. Gersbach

Abstract

Epigenome editing has rapidly evolved in recent years, with diverse applications that include elucidating gene regulation mechanisms, annotating coding and noncoding genome functions and programming cell state and lineage specification. Importantly, given the ubiquitous role of epigenetics in complex phenotypes, epigenome editing has unique potential to impact a broad spectrum of diseases. By leveraging powerful DNA-targeting technologies, such as CRISPR, epigenome editing exploits the heritable and reversible mechanisms of epigenetics to alter gene expression without introducing DNA breaks, inducing DNA damage or relying on DNA repair pathways.

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 07 Sep 2024)

[No new digest content identified]

Nature Genetics

Volume 56 Issue 8, August 2024

<https://www.nature.com/ng/volumes/56/issues/8>

Comment 22 Jul 2024

[Large-scale genotype prediction from RNA sequence data necessitates a new ethical and policy framework](#)

Genotype prediction from RNA sequencing (RNA-seq) data has become widespread, but there is a lack of clarity in current policy and inconsistency in data handling. To address this we call for a framework consisting of registered access for RNA-seq data, controlled access for genotypes, a code of conduct and enhanced downstream protections.

Mary A. Majumder, Jeffrey T. Leek, Amy L. McGuire

Perspective 08 Jul 2024

Establishing African genomics and bioinformatics programs through annual regional workshops

The African BioGenome Project (AfricaBP) Open Institute for Genomics and Bioinformatics established a series of regional workshops in 2023 to exchange knowledge and overcome barriers, which could serve as a model for other scientific communities.

Abdoallah Sharaf, Lucky Tendani Nesengani, ThankGod Echezona Ebenezer

Nature Human Behaviour

Volume 8 Issue 7, July 2024

<https://www.nature.com/nathumbehav/volumes/8/issues/7>

[Reviewed earlier]

Nature Medicine

Volume 30 Issue 8, August 2024

<https://www.nature.com/nm/volumes/30/issues/8>

Editorial

Every baby deserves access to genetic screening

Genomics-based newborn screening has the potential to revolutionize healthcare, but new solutions are needed to ensure that the benefits are equitably available.

Editorial 19 Aug 2024

News 15 Jul 2024

How mRNA is powering a personalized vaccine revolution

Dozens of clinical trials are testing new mRNA vaccines, using machine learning to identify antigens, and embracing new technologies such as self-amplifying RNA.

Mike May

World View 05 Jun 2024

The pandemic treaty: a grand global social bargain

The treaty is a grand social bargain of open sharing of crucial scientific data in real time and equitable allocation of lifesaving medical countermeasures.

Lawrence O. Gostin, Jianxi Gao

Article 02 Jul 2024

Healthcare system resilience and adaptability to pandemic disruptions in the United States

A natural experiment reports that US healthcare systems have substantial adaptability but only a moderate level of resilience to disruptions due to the COVID-19 pandemic.

Lu Zhong, Dimitri Lopez

Nature Reviews Drug Discovery

Volume 23 Issue 8, August 2024

<https://www.nature.com/nrd/volumes/23/issues/8>

[Reviewed earlier]

Nature Reviews Genetics

Volume 25 Issue 8, August 2024

<https://www.nature.com/nrg/volumes/25/issues/8>

[Reviewed earlier]

Nature Reviews Immunology

Volume 24 Issue 8, August 2024

<https://www.nature.com/nri/volumes/24/issues/8>

[Reviewed earlier]

New England Journal of Medicine

Volume 391 No. 9 September 5, 2024

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

NEJM Evidence

Volume 3 No. 8 August 2024

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 07 Sep 2024]

[No new digest content identified]

Pediatrics

Volume 154, Issue 2 August 2024

<https://publications.aap.org/pediatrics/issue/154/2>

[Reviewed earlier]

PharmacoEconomics

Volume 42, Issue 9 September 2024

<https://link.springer.com/journal/40273/volumes-and-issues/42-9>

[New issue; No digest content identified]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 07 Sep 2024)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 07 Sep 2024)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 07 Sep 2024)

[No new digest content identified]

PLoS Medicine

<https://journals.plos.org/plosmedicine/>

(Accessed 07 Sep 2024)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 07 Sep 2024)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 07 Sep 2024]

[No new digest content identified]

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 07 Sep 2024]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

September 3, 2024 vol. 121 no. 36

<https://www.pnas.org/toc/pnas/121/36>

Opinion August 28, 2024 Front Matter

[**The limits of doing global, cross-cultural behavioral science research**](#)

[Andrés Gvirtz and Anandita Sabherwal](#)

PNAS Nexus

Volume 3, Issue 7, July 2024

<https://academic.oup.com/pnasnexus/issue/3/7>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 39 - Issue 2 - April 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 184 July 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/184/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

August 2024 Volume 291 Issue 2028

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 232 Pages 1-208 (July 2024)

<https://www.sciencedirect.com/journal/public-health/vol/232/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 17, Issue 1-2, April/July 2024

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2024, Vol. 27, No. 1

<https://karger.com/phg/issue/27/1>

[Reviewed earlier]

Public Health Reports

Volume 139 Issue 4, July/August 2024

<https://journals.sagepub.com/toc/phrg/139/4>

[Reviewed earlier]

Qualitative Health Research

Volume 34 Issue 10, August 2024

<https://journals.sagepub.com/toc/QHR/current>

[New issue; No digest content identified]

Research Ethics

Volume 20 Issue 3, July 2024

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 07 Sep 2024]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Latest Articles

[No new digest content identified]

Risk Analysis

Volume 44, Issue 9 Pages: 1977-2311 September 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

[New issue; No digest content identified]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 07 Sep 2024]

[Reviewed earlier]

Science

Volume 385| Issue 6713| 6 Sep 2024

<https://www.science.org/toc/science/current>

[New issue; No digest content identified]

Science and Engineering Ethics

Volume 30, Issue 4 August 2024

<https://link.springer.com/journal/11948/volumes-and-issues/30-4>

[Reviewed earlier]

Science Translational Medicine

Volume 16| Issue 763| 4 Sep 2024

<https://www.science.org/toc/stm/current>

Viewpoint

[Precision adjuvants for pediatric vaccines](#)

By Anjali Singh, et al.

04 Sep 2024

An improved mechanistic understanding of immune development will guide age-appropriate adjuvant selection for safe and effective pediatric vaccines.

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 07 Sep 2024]

[No new digest content identified]

Social Science & Medicine

Volume 350 June 2024

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/350/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 07 Sep 2024]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 45, Issue 5 October 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-5>

[New issue; No digest content identified]

Travel Medicine and Infectious Diseases

Volume 60 July–August 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/60/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 29, Issue 8 Pages: i-iv, 657-755 August 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 42, Issue 22 17 September 2024

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/22>

Review article Open access

[Cultural and social attitudes towards COVID-19 vaccination and factors associated with vaccine acceptance in adults across the globe: A systematic review](#)

Tasniah Begum, Nikolaos Efsthathiou, Cara Bailey, Ping Guo

Article 125993

Review article Abstract only

[Exploration of individual socioeconomic and health-related characteristics associated with human papillomavirus vaccination initiation and vaccination series completion among adult females: A comprehensive systematic evidence review with meta-analysis](#)

George N. Okoli, Christine J. Neilson, Alexandra Grossman Moon, Hannah Kimmel Supron, ... Diane M. Harper

Article 125994

Research article Open access

[Effect of rotavirus vaccination on the burden of rotavirus disease and associated antibiotic use in India: A dynamic agent-based simulation analysis](#)

Alec Gleason, Chirag K. Kumar, Eili Klein, Ramanan Laxminarayan, Arindam Nandi

Article 126211

Research article Abstract only

[Impact of the COVID-19 pandemic on routine childhood vaccination in 9 U.S. jurisdictions](#)

Ashley Treharne, Bhavini Patel Murthy, Elizabeth R. Zell, Nkenge Jones-Jack, ... LaTreace Harris
Article 125997

Research article Open access

Knowledge, attitudes, and practices and long-term immune response after rVSVΔG-ZEBOV-GP Ebola vaccination in healthcare workers in high-risk districts in Uganda

Michelle A. Waltenburg, Markus H. Kainulainen, Amy Whitesell, Luke Nyakarahuka, ... Caitlin M. Cossaboom
Article 126031

Research article Abstract only

HPV Vaccine Issues in Japan: A review of our attempts to promote the HPV vaccine and to provide effective evaluation of the problem through social-medical and behavioral-economic perspectives

Asami Yagi, Yutaka Ueda, Tadashi Kimura
Article 125859

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 07 Sep 2024]

Open Access Article

Our Daughters—Ourselves: Evaluating the Impact of Paired Cervical Cancer Screening of Mothers with HPV Vaccination for Daughters to Improve HPV Vaccine Coverage in Bamako, Mali

by Tiffani Crippin, Karamoko Tounkara, Hayley Munir, Eliza Squibb, Caroline Piotrowski, Ousmane A. Koita, Ibrahima Teguété and Anne S. De Groot

Vaccines 2024, 12(9), 1019; <https://doi.org/10.3390/vaccines12091019> - 6 Sep 2024

Abstract

Cervical cancer (CC) is the second most common cancer in Western Africa, accounting for 12,000 cases and 6000 deaths annually. While vaccination against human papilloma virus (HPV) and CC screenings reduce the incidence and mortality of CC in many developed countries, 90% of [...]

Open Access Article

The Mpox Vaccine Hesitancy Scale for Mpox: Links with Vaccination Intention among Men Who Have Sex with Men in Six Cities of China

by Ying Gao, Shangbin Liu, Huifang Xu, Ying Wang, Gang Xu, Fan Hu, Jiechen Zhang and Yong Cai

Vaccines 2024, 12(9), 1009; <https://doi.org/10.3390/vaccines12091009> - 3 Sep 2024

Abstract

Background: Vaccine hesitancy is a significant barrier to achieving high vaccination rates, particularly among men who have sex with men (MSM), a group at increased risk for Mpox. This study aimed to develop and validate a Mpox vaccine hesitancy scale specifically tailored for [...]

Open Access Article

Population Movement and Poliovirus Spread across Pakistan and Afghanistan in 2023

by Irshad Ali Sodhar, Jaishri Mehraj, Anum S. Hussaini, Muhammad Aamir, Jahanuddin Mahsaud, Shabbir Ahmed, Ahmed Ali Shaikh, Asif Ali Zardari, Shumaila Rasool, Shoukat Ali Chandio and Erin M. Stuckey

Vaccines 2024, 12(9), 1006; <https://doi.org/10.3390/vaccines12091006> - 1 Sep 2024

Abstract

Population movement dynamics are a critical part of understanding communicable disease transmission patterns and determining where, when, and with whom to deliver appropriate prevention interventions.

This study aimed to identify the origin of the Afghan population and their patterns of movement within Karachi..

Value in Health

August 2024 Volume 27 Issue 8 p999-1174

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Development

Volume 180 August 2024

<https://www.sciencedirect.com/journal/world-development/vol/180/suppl/C>

[Reviewed earlier]

.....

.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....

.....

Pre-Print Servers

arxiv

<https://arxiv.org/>

[Accessed 07 Sep 2024]

[Filter: Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

[No new digest content identified]

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 07 Sep 2024]

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 07 Sep 2024]

[Filter: All articles]

[Exploring COVID-19 Pandemic Perceptions and Vaccine Uptake among Community Members and Primary Healthcare Workers in Nigeria: A Mixed Methods Study.](#)

Abiodun Sogbesan, Ayobami Adebayo Bakare, Sibylle Herzig Van Wees, Julius Salako, Damola Bakare, Omotayo E Olojede, Kofoworola Akinsola, Oluwabunmi Roseline Bakare, Adegoke G Falade, Carina King
medRxiv 2024.09.02.24312966; doi: <https://doi.org/10.1101/2024.09.02.24312966> Revision

[A Cross-Sectional Study on HPV Vaccine Awareness, Vaccination Willingness and Associated Factors among Male Healthcare Workers in Ethnic Minority-populated Areas in Southern China](#)

Chunlin Qin, Nian Jiang, Guorong Tang, Yun Zhou, Qingqing Liang

medRxiv 2024.09.02.24312968; doi: <https://doi.org/10.1101/2024.09.02.24312968>

[Acceptance of an Mpox Vaccine in the Democratic Republic of the Congo](#)

Skylar Petrichko, Jason Kindrachuk, Dalau Nkamba, Megan Halbrook, Sydney Merritt, Handdy Kalengi, Leonard Kamba, Michael Beya, Nicole A. Hoff, Christophe Luhata, Didine K. Kaba, Anne W. Rimoin

medRxiv 2024.08.15.24311971; doi: <https://doi.org/10.1101/2024.08.15.24311971> Revision

[Patient and Public involvement in the design of an international clinical trial: Real world experience](#)

Gwenda Simons, Helen Jones, Ian Clarke, Firoza Davies, Stacey Grealis, Elspeth Inch, Hameed Kahn, Joanne Lloyd, Al Richards, Hayley Rose, Ruth Williams, Maarten de Wit, Clarissa Woodcock, Leigh Romaniuk, Michelle Bardgett, Arthur G Pratt, Marie Falahee

medRxiv 2024.09.03.24312062; doi: <https://doi.org/10.1101/2024.09.03.24312062>

[Interplay Between the Gut Microbiome and Typhoid Fever: Insights from Endemic Countries and a Controlled Human Infection Model](#)

Philip M. Ashton, Leonardos Mageiros, James E. Meiring, Angeziwa Chunga Chirambo, Farhana Khanam, Happy Banda, Abhilasha Karkey, Sabina Dongol, Lorena Preciado Llanes, Helena Thomaidis-Brears, Malick Gibani, Nazmul Hasan Rajib, Nazia Rahman, Prasanta Kumar Biswas, Md Amirul Islam Bhuiyan, Sally Kay, Kate Auger, Olivier Seret, Nicholas R. Thomson, Andrew J Pollard, Stephen Baker, Buddha Basnyat, John D. Clemens, Christiane Dolecek, Sarah J. Dunstan, Gordon Dougan, Robert S. Heyderman, Virginia E. Pitzer, Firdausi Qadri, Melita A. Gordon, Thomas C. Darton, Kathryn E. Holt, STRATAA Study Group

medRxiv 2024.09.02.24312347; doi: <https://doi.org/10.1101/2024.09.02.24312347>

[Assessing Healthy Vaccinee Effect in COVID-19 Vaccine Effectiveness Studies: A National Cohort Study in Qatar](#)

Hiam Chemaitelly, Houssein H. Ayoub, Peter Coyle, Patrick Tang, Mohammad R. Hasan, Hadi M. Yassine, Asmaa A. Al Thani, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F. Abdul-Rahim, Gheyath K. Nasrallah, Mohamed Ghaith Al-Kuwari, Hamad Eid Al-Romaihi, Mohamed H. Al-Thani, Abdullatif Al-Khal, Roberto Bertollini, Adeel A. Butt, Laith J. Abu-Raddad

medRxiv 2024.07.28.24311115; doi: <https://doi.org/10.1101/2024.07.28.24311115> Revision

[Global Health Security Index Scores are associated with Covid-19 Pandemic Health and Macroeconomic Outcomes](#)

Matt Boyd, Michael G Baker, Nick Wilson

medRxiv 2024.09.02.24312964; doi: <https://doi.org/10.1101/2024.09.02.24312964>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-]
[No new digest content identified]

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 07 Sep 2024]

Selected Research

Research Article Open Access

REVISED- Empowering Global AMR Research Community: Interactive GIS dashboards for AMR data analysis and informed decision-making

[version 2; peer review: 1 approved with reservations, 1 not approved]

Stephen Obol Opiyo, Rachel Nalunkuma, Stella Maris Nanyonga, Nathan Mugenyi, Andrew Marvin Kanyike

Abstract

Background

Antimicrobial Resistance (AMR) is a critical global public health concern, demanding effective tools for research, data analysis, and decision-making. This study proposes a groundbreaking approach to empower the global AMR research community by introducing interactive Geographic Information System (GIS) dashboards. These dashboards aim to facilitate comprehensive data analysis of AMR across multiple countries, providing insights into antimicrobial usage (AMU), resistance patterns, and geographic distribution.

* * * *

Think Tanks

Brookings [to 07 Sep 2024]

<http://www.brookings.edu/>

Research

How the pandemic changed—and didn't change—where Americans are moving

Demographics & Population

Alan Berube

September 6, 2024

Center for Global Development [to 07 Sep 2024]

<https://www.cgdev.org/>

All Research

CGD NOTES

The Broken Wheel of Access for Antimicrobials: Barriers to Rolling out Antimicrobials in Low- and Middle-Income Countries

Katherine Klemperer et al.

September 05, 2024

Access to effective antimicrobials is crucial to any healthcare system, but in many countries, necessary antimicrobials are not available to patients because they have not been registered and/ or introduced. This introduction barrier is particularly prevalent in low- and middle-income countries (LMI...

Chatham House [to 07 Sep 2024]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [to 07 Sep 2024]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 07 Sep 2024]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

Kaiser Family Foundation [to 07 Sep 2024]

https://www.kff.org/search/?post_type=press-release

Newsroom

No new digest content identified.

McKinsey Global Institute [to 07 Sep 2024]

<https://www.mckinsey.com/mgi/overview>

Latest Research

No new digest content identified.

ODI [Overseas Development Institute] [to 07 Sep 2024]

<https://odi.org/en/publications/>

Publications [Selected]

No new digest content identified.

Pew Research Center [to 07 Sep 2024]

<https://www.pewresearch.org/>

Latest Publications [Selected]

short reads Sep 5, 2024

[Most people in 35 countries see the UN favorably, but views have dipped in some places](#)

A median of 58% across 35 countries have a favorable view of the organization, while 31% have a negative view.

Rand [to 07 Sep 2024]

<https://www.rand.org/pubs.html>

Published Research [Selected]

No new digest content identified.

Urban Institute [to 07 Sep 2024]

<https://www.urban.org/publications>

[New Research Publications - Selected](#)

World Economic Forum [to 07 Sep 2024]

<https://agenda.weforum.org/press/>

Media [Selected]
No new digest content identified.

.....
.....

Public Consultations/Call for Inputs/Call for Papers

Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

A Notice by the Food and Drug Administration on 08/20/2024 Comments received **on or before September 12, 2024**, will be provided to the committee.

[Pertussis controlled human infection models (CHIMs)]

The meeting will be held virtually on September 20, 2024, from 8:30 a.m. to 5 p.m. Eastern Time.
SUMMARY:

The Food and Drug Administration (FDA or we) announces a forthcoming public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee (the committee). The general function of the committee is to provide advice and recommendations to FDA on regulatory issues. The committee will discuss considerations related to the use of pertussis controlled human infection models (CHIMs) in pivotal studies to demonstrate efficacy of pertussis vaccines for the purpose of licensure and will hear an overview of the Laboratory of Mucosal Pathogens and Cellular Immunology (LMPCI) research program in the Center for Biologics Evaluation and Research (CBER). At least one portion of the meeting will be closed to the public. FDA is establishing a docket for public comment on this document.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available on FDA's website at the time of the advisory committee meeting. Background material and the link to the online teleconference and/or video conference meeting will be available at: <https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm>. Scroll down to the appropriate advisory committee meeting link. The meeting will include slide presentations with audio and video components to allow the presentation of materials in a manner that most closely resembles an in-person advisory committee meeting.

Call for Public Comment: General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies that Utilize Real-World Data for Safety Assessment of Medicines.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use]

The guideline will focus on non-interventional pharmacoepidemiological studies using Real-World Data (RWD) and will include basic principles that may apply to these studies when real-world data elements are included.

Public consultation dates [announced to date]:

ANVISA, Brazil - Deadline for comments by 24 August 2024

FDA, United States - Deadline for comments by 3 September 2024

MFDS, Republic of Korea - Deadline for comments by 15 July 2024

MHLW/PMDA, Japan - Deadline for comments by 28 July 2024

NMPA, China - Deadline for comments by 12 October 2024

TFDA, Chinese Taipei - Deadline for comments by 30 September 2024

Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

A Notice by the Food and Drug Administration on 08/20/2024 Comments received **on or before September 12, 2024**, will be provided to the committee.

[Pertussis controlled human infection models (CHIMs)]

The meeting will be held virtually on September 20, 2024, from 8:30 a.m. to 5 p.m. Eastern Time.
SUMMARY:

The Food and Drug Administration (FDA or we) announces a forthcoming public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee (the committee). The general function of the committee is to provide advice and recommendations to FDA on regulatory issues. The committee will discuss considerations related to the use of pertussis controlled human infection models (CHIMs) in pivotal studies to demonstrate efficacy of pertussis vaccines for the purpose of licensure and will hear an overview of the Laboratory of Mucosal Pathogens and Cellular Immunology (LMPCI) research program in the Center for Biologics Evaluation and Research (CBER). At least one portion of the meeting will be closed to the public. FDA is establishing a docket for public comment on this document.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available on FDA's website at the time of the advisory committee meeting. Background material and the link to the online teleconference and/or video conference meeting will be available at: <https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm>. Scroll down to the appropriate advisory committee meeting link. The meeting will include slide presentations with audio and video components to allow the presentation of materials in a manner that most closely resembles an in-person advisory committee meeting.

* * * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2024. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable

development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

| | | | |
|---|---|---|---|
| * | * | * | * |
| * | * | * | * |